How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
General Anaesthetic Medication Market
- By Drug Type: Inhalational Anesthetics, Intravenous Anesthetics, Adjunct Anesthetics
- By Inhalational Anesthetic Type: Sevoflurane, Isoflurane, Desflurane, Nitrous Oxide
- By Intravenous Anesthetic Type: Propofol, Etomidate, Ketamine, Thiopental
- By Application: Surgical Procedures, Diagnostic Procedures, Dental Procedures
- By End User: Hospitals, Ambulatory Surgical Centers, Dental Clinics
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Inhalational Anesthetics leads By Drug Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.173 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.181 →
Full report · locked preview
Everything inside the General Anaesthetic Medication Market report
A complete, evidence-based study - 12 chapters and 121 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
By Drug Type 3
By Inhalational Anesthetic Type 4
By Intravenous Anesthetic Type 4
By Application 3
By End User 3
Companies profiled
AbbVie Inc.
Baxter International Inc.
Fresenius Kabi
B. Braun Melsungen AG
Mylan N.V. (Viatris)
Pfizer Inc.
Hikma Pharmaceuticals PLC
Sagent Pharmaceuticals Inc.
Lundbeck A/S
Meda AB (subsidiary of Mylan/Viatris)
Hospira (a Pfizer company)
Boehringer Ingelheim GmbH
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Fresenius Kabi
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →B. Braun Melsungen AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mylan N.V. (Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Hikma Pharmaceuticals PLC
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Sagent Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Lundbeck A/S
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Meda AB (subsidiary of Mylan/Viatris)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Hospira (a Pfizer company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Boehringer Ingelheim GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Teva Pharmaceutical Industries Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sandoz (a Novartis division)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Amneal Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,197M by 2033 · 5.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Inhalational Anesthetics68.0
- Intravenous Anesthetics17.3
- Adjunct Anesthetics14.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,119M → $1,747M · 5.7%
Europe$779.7M → $1,065M · 4.0%
Asia Pacific$711.9M → $1,206M · 6.8%
Latin America$440.7M → $698.8M · 5.9%
Middle East and Africa$339.0M → $573.5M · 6.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.442026
5.442027
5.472028
5.472029
5.492030
5.492031
5.502032
5.532033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- AbbVie Inc.21.5
- Baxter International Inc.17.0
- Fresenius Kabi11.3
- B. Braun Melsungen AG10.1
- Mylan N.V. (Viatris)7.6
- Pfizer Inc.4.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →By Drug Type13.8%
By Inhalational Anesthetic Type28.8%
By Intravenous Anesthetic Type22.5%
By Application21.2%
By End User13.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.0
- Europe20.1
- Asia Pacific22.8
- Latin America13.2
- Middle East and Africa10.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | 84 | 90 | 92 | 87 | 93 | 94 | 90 |
| Baxter International Inc. | 80 | 88 | 77 | 84 | 88 | 93 | 85 |
| Fresenius Kabi | 65 | 65 | 70 | 77 | 73 | 82 | 72 |
| B. Braun Melsungen AG | 64 | 68 | 58 | 70 | 69 | 77 | 68 |
| Mylan N.V. (Viatris) | 62 | 51 | 64 | 56 | 69 | 54 | 59 |
| Pfizer Inc. | 68 | 66 | 51 | 71 | 48 | 52 | 59 |
| Hikma Pharmaceuticals PLC | 61 | 48 | 63 | 45 | 51 | 64 | 55 |
| Sagent Pharmaceuticals Inc. | 54 | 58 | 38 | 44 | 35 | 37 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- AbbVie Inc.
- Baxter International Inc.
- Fresenius Kabi
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| AbbVie Inc. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Baxter International Inc. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Fresenius Kabi | − | ◐ | − | ✓ | ◐ | ✓ |
| B. Braun Melsungen AG | − | ◐ | − | − | ◐ | ◐ |
| Mylan N.V. (Viatris) | − | ◐ | − | − | ◐ | − |
| Pfizer Inc. | ◐ | ◐ | − | − | − | − |
| Hikma Pharmaceuticals PLC | ◐ | − | ◐ | − | − | ◐ |
| Sagent Pharmaceuticals Inc. | ◐ | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1AbbVie Inc.90
2Baxter International Inc.85
3Fresenius Kabi72
4B. Braun Melsungen AG68
5Mylan N.V. (Viatris)59
6Pfizer Inc.59
7Hikma Pharmaceuticals PLC55
8Sagent Pharmaceuticals Inc.44
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
AbbVie Inc.Baxter International Inc.
Challenger2
Strong scale, closing on the leaders.
Fresenius KabiB. Braun Melsungen AG
Contender2
Focused players with pockets of strength.
Mylan N.V. (Viatris)Pfizer Inc.
Niche2
Specialists in a single segment or region.
Hikma Pharmaceuticals PLCSagent Pharmaceuticals Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land By Drug Type in North America, then scale across General Anaesthetic Medication Market — a $493M beachhead inside a $8.38B market.
Beachhead (SOM)$493Mobtainable near-term
Serviceable (SAM)$3.41Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Inhalational Anesthetics
Best fit — highest urgency & budget in By Drug Type.
Economic buyer80 fit
Intravenous Anesthetics
Strong fit — clear ROI and a fast path to value.
End user66 fit
Adjunct Anesthetics
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win By Drug Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add By Inhalational Anesthetic Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + By Intravenous Anesthetic Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales48%
Partner / channel27%
Digital / self-serve17%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For By Drug Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win General Anaesthetic Medication Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified22%
Evaluation15%
Closed-won7%
$9.7KCAC
$52KLTV
5.3:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
General Anaesthetic Medication Market is a resilient opportunity — $1.25B by 2033, compounding at 3.7%.
TAM · 2025$937Mtoday
TAM · 2033$1.25Bforecast
CAGR3.7%2027–2033
Cumulative$9.78Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.25BTotal addressable market
SAM$502MServiceable available market
SOM$82MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.7% CAGR
Demand compounds through 2033, outpacing GDP across By Drug Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in By Drug Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.25BLarge & growingTAM by 2033 at 3.7% CAGR
$502MServiceable nowreachable with today’s model
$82MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$974MBear2.4% CAGR
$1.25BBase3.7% CAGR
$1.60BBull4.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & By Inhalational Anesthetic Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
General Anaesthetic Medication Market — a $1.46B market by 2033. Plan: grow share from 11.3% to 17.6%.
Market size · 2033$1.46Btotal addressable
Market CAGR4.5%2027–2033
Target share17.6%from 11.3% today
Revenue ambition$256Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 11.3% | 17.6% | Ahead |
| Revenue | $159M | $256M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 29.4% | 41.7% | On track |
| Customer retention | 90.2% | 92.1% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in By Drug Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build By Inhalational Anesthetic Type capability
A defensible second engine — invest in By Inhalational Anesthetic Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core By Drug Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch By Inhalational Anesthetic Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $37M capacity & capability investment
- Greenlight bolt-on M&A in By Inhalational Anesthetic Type
- Authorise North America expansion plan
- Fund R&D program for By Drug Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the General Anaesthetic Medication Market conversation — a $5.81B market you can size, segment and defend in minutes.
Market size · 2033$5.81Btotal opportunity
Growth8.8%CAGR to 2033
Addressable buyers1,175+accounts in scope
Typical ROI6.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of By Drug Type
Goal Grow share in By Drug Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.4×return on cost, year one
< 4 mopayback period
$79K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
AbbVie Inc.Baxter International Inc.Fresenius KabiB. Braun Melsungen AGMylan N.V. (Viatris)Pfizer Inc.Hikma Pharmaceuticals PLCSagent Pharmaceuticals Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your General Anaesthetic Medication Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
General Anaesthetic Medication Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Gene Prediction Tool Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportGene Mutation Detection Kit Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportGene Gun Biolistic Particle Delivery System Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportGene Fragment Synthesis Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportGene Fragment Market
Gene Fragment Market is valued at USD 842 Million in 2025 and is expected to reach USD 1.47 Bil…
$842M market · 2025 base year
View reportGene Expression System Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportGene Expression Software Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportGene Expression Screening Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportGene Expression Microarray Platform Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportGene Expression Chip Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportGene Expression and Transcriptome Sequencing Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportLaser Safety Eyewears Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.